Zhang Hua, deputy general manager of Yuekang Pharmaceutical Company, predicts that employees will work overtime and the production line will continue to pay three times the salary of a threex salary to employees after the new year of the lunar calendar., Guarantee supply during the Spring Festival.
After the surge in crown disease infection, China faces the crisis of drug shortage. The local pharmaceutical companies open their horsepower before the Lunar New Year, and urgently apply for new production equipment to increase the supply of crown -related drugs.Chinese officials in charge of medical supplies say that "confidence and ability" to ensure the treatment of hospitals for treatment of hospitals.
Yuekang Pharmaceutical, headquartered in Beijing, was included in the list of guaranteeing supply companies on the 10th of last month, and produced compound aminoporamine capsules containing Paracetamol ingredients.
The company's deputy general manager Zhang Tuesday (January 10) in an interview with an interview organized by the Chinese official organization that before the Chinese epidemic set out in December last year, the company produced by the company's compound aminopolycamine capsule capsule capsuleThe daily output is only 30,000 boxes, which are mainly supplied to the Beijing area; now the company has opened all production lines and runs 24 hours a day. The daily output increases to 150,000 boxes.
The capital Beijing took the lead in greeting the peak of infection after the outbreak of the Chinese epidemic in this round, and the epidemic then quickly spread in other regions.Zhang will say: "Other parts of the country are now much larger than Beijing."
He predicts that the employee's overtime point and the production line will continue to be until the Lunar New Year. The company also prepares to pay the employee three times the salary to ensure the supply during the Spring Festival.
Yuekang Pharmaceutical also submits an application for equipment changes to the relevant departments a week ago. It is currently waiting for approval. It is expected that after the new equipment is approved, the daily compound aminamine capsule capsule production will increase to 1 million boxes.
China ’s“ clear zero ”policy that lasted three years last month last month, but the withdrawal of the tsunami of the epidemic caused hospitals and pharmacies in various places caught off guard.The Chinese people have also returned to China from local purchases.
In addition to the shortage of antipyretic drugs, oral drugs for coronary virus are difficult to find in China.Paxlovid, a oral drug produced by Pfizer, was fired to tens of thousands of yuan per box (about S $ 1960) per box in the black market.In response to demand, Chinese officials have also instructed pharmaceutical companies to speed up the production of domestic crown disease.
The Pharmaceutical Company China Resources Shuanghe received a notice from the Ministry of Industry and Information on the 2nd of this month to fully start Azfdin production.Azfding, developed by Henan Real Biotechnology Company, is currently the only Chinese domestic small molecular anti -crown -resistant oral medication.
Wang Lili, general manager of the Division of China Resources Shuanghe Industrial Park, introduced in an interview that the first batch of Azfding produced in the park is expected to be available on the 19th of this month.At present, the company is conducting a large -scale production process verification; once approved, it will be able to provide 80 million pieces of Azfdin to the market by the end of this month.
China Resources Shuanghe has also started the production line mold improvement.Wang Lili predicts that after completing the mold improvement in mid -February, the daily production production of the park's daily Azf will increase from 7 million to 12 million pieces.She said: "At present, the employees of the Azfding production line in the park are produced in 24 hours, and they are full of holidays and strive to produce more products."
In response to the supply of crown -related drugs, Zhou Jian, deputy director of the Consumer Department of the Ministry of Industry and Information Technology, said that he is actively promoting the expansion of enterprises to expand production and strengthen the supply of key drug markets.Priority to ensure medical supplies for medical institutions, nursing homes, welfare homes and other key places, and "confidence and ability" to ensure the medical needs of hospital treatment.
Pfizer plans to cooperate with China Pharmaceutical Factory to produce coronary drugs in China Paxlovid
The United States Pfizer revealed that it plans to cooperate with Chinese pharmaceuticals to produce Paxlovid in China in the first half of this year.
According to Reuters, President President Albert Bourla on Monday (January 9) at the JP Morgan Chase Medical Care Conference held in San Francisco, he denied that Pfizer would produce and sell PaxLovid's PaxLovidic drugs in China.
But he said that the company will directly cooperate with Chinese partners to produce PAXLOVID locally, and it is expected to start production in the first half of the year.Alber did not disclose the name of Chinese partners.
Zhou Jian, deputy director of the Consumer Department of the Ministry of Industry and Information Technology, was questioned at a media event on Tuesday, and did not confirm the news that Paxlovid would produce in China, only emphasizing that "commissioning production is a business behavior."But he said: "As far as I know, Pfizer has reached an agreement to commission production with Chinese pharmaceutical companies Huahai Pharmaceutical in August last year."
Huahai Pharmaceutical responded to investors on Tuesday on a investment platform that it is actively cooperating with Pfizer to accelerate the various tasks of the localization of the PaxLovid localization project to ensure the sufficient supply of PaxLovid in the Chinese market.
China has approved two imported crown disease oral medicines so far.In addition to PaxLovid, another crown disease oral medication approved at the end of last month is Molnupiravir developed by the American Pharmaceutical Company Merck (known as Merida).
As for whether China will increase the import of foreign coronary drugs under the surge in infection, Zhou Jian said: "This is a business problem."
China National Medical Insurance Bureau said on the 8th that the negotiations with Pfizer's drug treatment drugs were unsuccessful because Paxlovid's offer was too high.This means that after March 31, Paxlovid will be removed from the list of Chinese medical insurance directory.
In response, Aberle responded on Monday that the offer required by China is lower than the minimum quotation of middle -income countries. "As the second largest economy in the world, I don't think China should pay a lower price than Salvador."
